For the quarter ending 2025-09-30, NRXS had -$1,611,347 decrease in cash & cash equivalents over the period. -$1,427,539 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net revenue | 2,601,155 | - |
| Cost of goods sold | 421,265 | - |
| Gross profit | 2,179,890 | - |
| Selling expenses | 1,694,354 | - |
| Research and development | 347,433 | - |
| Compensation and benefits | 3,456,406 | - |
| Professional services | 989,301 | - |
| Other operating expenses | 1,805,436 | - |
| Operating loss | -6,113,040 | - |
| Financing charges | 30,240 | - |
| Interest expense | 45,333 | - |
| Change in fair value of warrant liability | 28 | - |
| Other income | 96,743 | - |
| Total other income (expense), net | 21,142 | - |
| Net loss | -2,122,796 | -3,969,102 |
| Provision for losses on inventory | 11,598 | 12,741 |
| Depreciation and amortization | 16,205 | 19,241 |
| Provisions for losses on accounts receivable | 2,200 | 0 |
| Amortization of debt discount and issuance cost | - | 0 |
| Loss on disposal of property and equipment | -7,710 | -168 |
| Non-cash lease expense | -20,563 | 28,001 |
| Issuance of warrants for non-cash consideration | - | 0 |
| Stock-based compensation | 160,862 | 278,854 |
| Issuance of common stock for non-cash consideration | -546 | 0 |
| Financing charges | 30,240 | - |
| Change in fair value of warrant liabilities | -1,740 | 1,712 |
| Accounts receivable | -17,814 | -116,100 |
| Inventory | -9,578 | 99,845 |
| Prepaids and other current assets | -122,829 | -32,295 |
| Accounts payable | 421,881 | -132,430 |
| Accrued expenses | 138,170 | 407,812 |
| Other non-current liabilities | - | 267,540 |
| Customer deposits | 5,233 | -600 |
| Operating lease liability | -6,278 | -30,208 |
| Other non-current assets and liabilities | -44,124 | - |
| Net cash used in operating activities | -1,427,539 | -3,071,145 |
| Additions to property and equipment | 0 | 25,288 |
| Proceeds from convertible notes, net of fees | - | 0 |
| Net cash used in investing activities | 0 | -25,288 |
| Offering costs paid | 113,617 | 459,999 |
| Proceeds from issuance of common shares | 0 | 4,999,999 |
| Proceeds from exercised warrants | 0 | 1,002,991 |
| Principal payments on notes payable | 70,191 | 154,972 |
| Net cash provided by financing activities | -183,808 | 5,388,019 |
| Net increase in cash and cash equivalents | -1,611,347 | 2,291,586 |
| Cash and cash equivalents at beginning of period | 3,696,870 | - |
| Cash and cash equivalents at end of period | 4,377,109 | - |
Neuraxis, INC (NRXS)
Neuraxis, INC (NRXS)